Astrana Health (NASDAQ:ASTH) Price Target Lowered to $50.00 at Truist Financial

Astrana Health (NASDAQ:ASTH) had its price objective decreased by Truist Financial from $59.00 to $50.00 in a report released on Monday morning,Benzinga reports. Truist Financial currently has a buy rating on the stock.

Several other research analysts have also commented on ASTH. KeyCorp started coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Macquarie raised shares of Astrana Health to a “hold” rating in a research report on Monday, December 16th. TD Cowen initiated coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target for the company. Finally, Robert W. Baird raised their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $63.67.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $30.28 on Monday. The firm has a market capitalization of $1.70 billion, a PE ratio of 23.29, a price-to-earnings-growth ratio of 1.80 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. The business’s fifty day moving average price is $39.55 and its 200 day moving average price is $47.05. Astrana Health has a 12 month low of $29.08 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter last year, the company earned $0.47 EPS. On average, sell-side analysts anticipate that Astrana Health will post 1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Central Pacific Bank Trust Division acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $160,000. SG Americas Securities LLC bought a new stake in shares of Astrana Health during the 3rd quarter worth about $680,000. Granite Bay Wealth Management LLC bought a new position in Astrana Health during the third quarter valued at about $290,000. Handelsbanken Fonder AB bought a new position in shares of Astrana Health in the third quarter valued at $492,000. Finally, GAMMA Investing LLC purchased a new position in shares of Astrana Health in the third quarter worth approximately $34,000. 52.77% of the stock is owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.